Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

被引：0

作者：

Hungria, Vania ^{[1
]}

Weisel, Katja ^{[2
]}

Currie, Brooke ^{[3
]}

Perera, Sue ^{[4
]}

Sule, Neal ^{[5
]}

He, Wei ^{[6
]}

Davy, Katherine ^{[7
]}

McKeown, Astrid

Sapra, Sandhya ^{[5
]}

Nelsen, Linda ^{[5
,6
]}

Li, Mary ^{[5
]}

Barale, Sophie ^{[8
]}

Boyle, Julia ^{[4
]}

McPoyle, Kaytlyn ^{[5
]}

Dimopoulos, Meletios Athanasios ^{[9
]}

机构：

[1] Clin Sao Germano, Dept Hematol, Sao Paulo, Brazil

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] GSK, Rockville, MD USA

[4] GSK, London, England

[5] GSK, Upper Providence, PA USA

[6] GSK, Waltham, MA USA

[7] GSK, Stevenage, Herts, England

[8] GSK, Paris, France

[9] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

来源：

关键词：

multiple myeloma; belantamab mafodotin; relapsed/refractory multiple myeloma; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-510

引用

页码：S505 / S505

页数：1